Predicting the metabolic characteristics of neorudin, a novel anticoagulant fusion protein, in patients with deep vein thrombosis.
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis research"
DOI: 10.1016/j.thromres.2020.05.048
Abstract: INTRODUCTION Recombinant neorudin (EPR-hirudin, EH) is an inactive prodrug that is converted to its active metabolite, hirudin variant 2-Lys47 (HV2), at the thrombus site. We aimed to investigate the mechanism underlying site-selective bioconversion of EH… read more here.
Keywords: hv2 thrombus; hv2; site; patients deep ... See more keywords